Quality Improvement Program (QIP) to Reduce 30-Day Readmission in Malnourished Hospitalized Patients

Does a Rapid, Comprehensive Oral Nutritional Supplementation Quality Improvement Program (QIP) Reduce 30-Day Readmission in Malnourished Hospitalized Patients?

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02262429

Enrollment

2386

Registered

2014-10-13

Start date

2014-10-31

Completion date

2015-08-31

Last updated

2015-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Brief summary

Newly admitted patients will be screened for risk of malnutrition. Patients will receive either the feeding protocol or current oral nutrition supplement (ONS) practice, pending location. Patients will continue the nutrition plan taking the supplement post discharge. Study team will follow-up with telephone calls to help support post-discharge ONS compliance. Quality and service utilization data will be gathered for analysis.

Interventions

OTHERONS QIP

Rapid comprehensive ONS, dietary consult, follow up phone calls

OTHERONS Standard Feeding

Standard of care

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient is ≥ 18 years of age. * Patient is screened for malnutrition with an MST score ≥ 2 (see Appendix C). * Patient has length of stay of hospital stay \> 2 days. * Patient is able to consume foods and beverages orally. * Patient receives Ensure, Nepro or Glucerna during the course of his or her hospital stay in connection with the QIP.

Exclusion criteria

* Patient is pregnant. * Patient is intubated, receiving tube feeding or parenteral nutrition. * Patient unable to provide HIPAA authorization and informed consent. * Patient is discharged to hospice care. * Patient has a condition that would preclude ingestion / absorption of the oral nutritional supplements, including allergic response to any ONS ingredient. * Patient has severe dementia or delirium, brain metastases, eating disorder, history of significant neurological or psychiatric disorder. * Patient has stated an allergy or intolerance to any of the ingredients in the study products.

Design outcomes

Primary

Measure	Time frame	Description
Post-discharge readmissions	November 2014 - April 2015, 30 days post discharge	Non-elective readmission 30 days post discharge.

Secondary

Measure	Time frame	Description
Hospital length of stay	October 2014 - March 2015, up to 6 months	Length of stay in the hospital will be calculated by looking at the admission and discharge dates.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026